Korean bioventures join an inaugural matching event with Japanese pharma firms at Shonan iPark, amid rising hopes for further bilateral partnerships based on respective R&D capabilities.

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Machines are now generating molecules that “no human would have imagined,” heard delegates at the BioAsia 2024 summit in Hyderabad, as big pharma and tech leaders discussed the many ways in which AI is causing fundamental shift in R&D approaches.

The digital “agent” on the horizon will draw on users’ entire health record, data from wearables and other sources to steer them in making health decisions. In this second part of a two-part series, Andrew Trister, chief scientific officer and chief medical officer at Verily, discusses his vision for the future and current obstacles.